News: CTX-derived Exosomes

10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.

Read more…

14 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is partnering with the University of Cardiff under a new grant-funded collaboration utilising ReNeuron’s exosome-based drug delivery technology platform.

Read more…

16 July 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.

Read more…

8 May 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces a year-end business update ahead of its preliminary results for the year ended 31 March 2019, which will be announced on Thursday 11 July 2019.

Read more…

31 January 2019 : ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes will be presented today at a leading US forum on the manufacture of cell and gene therapies.

Read more …

 

4 January 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a collaboration agreement with a US-based biopharmaceutical company to explore the use of the Company’s exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.

Read more…

 

 

04 May 2018:ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is today, as previously announced, hosting a capital markets event focused on the Company’s exosome nanomedicine platform.

Read more…

04 May 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new and positive pre-clinical data relating to its ExoPr0 stem cell-derived exosome therapy candidate will be presented today at ISCT 2018, a leading scientific conference taking place this week in Montreal, Canada.

Read more…

27 October 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is the lead industry participant in a new grant award from the Welsh Government to advance its emerging exosome therapy platform.

Read more…

11 October 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at major scientific conference.

Read more…